Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
PATOU GARY reported acquisition or exercise transactions in this Form 4 filing.
Xenon Pharmaceuticals director Gary Patou reported several equity compensation moves. He received a grant of 1,593 restricted share units (RSUs) and a separate grant of 10,507 share options with a strike price of $53.4600 per share expiring on June 2, 2036. Earlier, on June 1, 2026, 2,645 RSUs from a prior award vested 100% and were settled into the same number of common shares, lifting his direct common share holdings to 26,218 shares. The filing also shows 4,902 common shares held indirectly through the Gary & Karen Barbara Patou trustees of the Patou Family Trust.
Xenon Pharmaceuticals Inc. director Patrick Machado reported multiple equity awards and an option exercise. On June 1, 2026, 2,645 Restricted Share Units (RSUs) vested, converting into 2,645 Common Shares, all held directly. On June 3, 2026, he received 1,593 additional RSUs and an option grant for 10,507 shares with a $53.4600 exercise price, expiring on June 2, 2036. The newly granted RSUs and options are scheduled to vest or become exercisable in connection with the issuer’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Justin D. Gover reported equity compensation and an option exercise. He exercised 2,645 Restricted Share Units into 2,645 Common Shares on June 1, 2026, reflecting a 100% vesting of an RSU award originally granted on June 5, 2025.
On June 3, 2026, he received 1,593 Restricted Share Units and a Share Option for 10,507 Common Shares at an exercise price of $53.4600 per share, expiring on June 2, 2036. Both the new RSUs and the option vest 100% on the earlier of June 1, 2027 or the day before Xenon’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Elizabeth A. Garofalo reported compensation-related equity transactions with no open-market buying or selling. On June 1, 2026, 2,645 Restricted Share Units vested and were exercised into 2,645 Common Shares, fully settling that RSU award. On June 3, 2026, she received 1,593 new Restricted Share Units and an option to purchase 10,507 Common Shares at an exercise price of $53.4600 per share, both vesting 100% on the earlier of June 1, 2027 or the day before the 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Steven Gannon reported routine equity compensation and related share movements. He received 1,593 restricted share units (RSUs) that each entitle him to one common share, vesting 100% on the earlier of June 1, 2027 or the day before the 2027 annual shareholder meeting. He was also granted options to buy 10,507 common shares at an exercise price of $53.46 per share, expiring in 2036. Separately, 2,645 RSUs granted in 2025 fully vested on June 1, 2026 and were settled into the same number of common shares; 1,416 of those shares were withheld by the company at a price of $53.41 per share to cover tax obligations, which the company notes does not represent a sale. After these transactions, Gannon directly holds 11,870 common shares.
Xenon Pharmaceuticals Inc. director Gillian Cannon reported routine equity compensation and an option exercise. She received 1,593 Restricted Share Units and 10,507 share options with an exercise price of $53.4600 per share, each tied to future vesting. Separately, 2,645 RSUs granted on June 5, 2025 fully vested on June 1, 2026 and were settled into an equal number of common shares. The new RSU grant and options vest 100% on the earlier of June 1, 2027 or the day before the company’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals director Dawn Svoronos reported routine equity compensation activity. Previously granted restricted share units vested into 2,645 Common Shares, and the company withheld 1,416 shares at $53.41 to cover income taxes, which the filing notes does not represent a sale.
Following these transactions, she directly holds 26,229 Common Shares. On the same date, she received new awards of 1,593 restricted share units and options for 10,507 shares with a $53.46 exercise price expiring on June 2, 2036, both vesting in full around the issuer’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals Inc. reported results of its annual meeting of shareholders held on June 2, 2026. Shareholders approved a new 2026 Equity Incentive Plan to replace the prior 2014 plan, following the Board of Directors’ recommendation.
Shareholder turnout was high, with 90,399,636.29 common shares, representing approximately 93.54% of shares entitled to vote, present or represented by proxy. All director nominees were elected, the advisory "say‑on‑pay" vote on executive compensation was approved, and shareholders supported holding this advisory vote every one year. Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent auditor and authorized the audit committee to set the auditor’s remuneration.
XENON PHARMACEUTICALS INC. Schedule 13G/A reports that Janus Henderson Group plc and its Asset Managers are deemed to beneficially own 4,175,982 common shares, representing 4.5% of the outstanding common stock as reported. The filing clarifies voting and dispositive power is exercised shared by the Asset Managers.
Xenon Pharmaceuticals reports beneficial ownership by Avoro Capital Advisors LLC and Behzad Aghazadeh of 5,777,777 shares of common stock, representing 6.26% of the class. The percentage is calculated using 92,247,633 Common Shares outstanding as reported in the Company’s March 12, 2026 prospectus supplement after the underwriters' overallotment exercise. The filing is an amendment to a Schedule 13G/A that updates ownership details filed by the reporting persons.